A 29-year-old cisgender woman recently diagnosed with HIV presents to clinic for follow-up. Her baseline laboratory studies showed a CD4 count of 257 cells/mm3 and an HIV RNA level of 42,690 copies/mL. She initially took bictegravir-tenofovir alafenamide-emtricitabine for about 10 days but did not tolerate it due to sleep problems and is not willing to take any other similar regimen. She is asking to receive a single tablet regimen. She is HLA-B*5701 positive. You discuss possible single-tablet regimen options and are planning to use a regimen with a non-nucleoside reverse transcriptase inhibitor (NNRTI) for the anchor drug.
Which one of the following is TRUE about the following single-tablet non-nucleoside reverse transcriptase inhibitor (NNRTI)-based options?
Figure 1. Pooled Data From ECHO and THRIVE Studies: Virologic Response by Baseline HIV RNA Level.
Source: Cohen CJ, Molina JM, Cahn P, et al. Efficacy and safety of rilpivirine (TMC278) versus efavirenz at 48 weeks in treatment-naive HIV-1-infected patients: pooled results from the phase 3 double-blind randomized ECHO and THRIVE Trials. J Acquir Immune Defic Syndr. 2012;60:33-42.
Figure 2. 48-Week Virologic Data in the DRIVE AHEAD Studt
Source: Orkin C, Squires KE, Molina JM, et al. Doravirine/Lamivudine/Tenofovir Disoproxil Fumarate is Non-inferior to Efavirenz/Emtricitabine/Tenofovir Disoproxil Fumarate in Treatment-naive Adults With Human Immunodeficiency Virus-1 Infection: Week 48 Results of the DRIVE-AHEAD Trial. Clin Infect Dis. 2019;68:535-44.
Sign In or Register Progress Not Saved!
Since you are not signed in, your progress won't be saved.
Since you are not signed in, your progress won't be saved.
Question Last Updated
September 21st, 2023
September 21st, 2023
Steps to Acquire CE for this Question Bank Topic:
1
Answer
Answer all questions
2
Score 80%+
Answer correctly
3
Claim CE
Choose CNE or CME
4
Give Feedback
Complete survey
5